2012

• Goldstein, D., Spry, N., Cummins, M., Brown, C., van Hazel, G., Carroll, S., Selva-Nayagam, S., Borg, M., Ackland, S., Wratten, C., Shapiro, J., Porter, I., Hruby, G., Horvath, L., Bydder, S., Underhill, C., Harvey, J., Gebski, V. (2012), The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. British Journal of Cancer. 106(1), 61-69. [Abstract]
• Randall, S., McKay, M., Pascovici, D., Mahon, K., Horvath, L., Clarke, S., Molloy, M. (2012), Remarkable temporal stability of high-abundance human plasma proteins assessed by targeted mass spectrometry. Proteomics - Clinical Applications. 6(11-12), 626-634. [Abstract]
• Femia, G., Hardy, T., Spies, J., Horvath, L. (2012), Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: a case report and literature review. Asia Pacific Journal of Clinical Oncology. 8(2), 115-122. [Abstract]
• Savdie, R., Horvath, L., Benito, R., Rasiah, K., Haynes, A., Chatfield, M., Stricker, P., Turner, J., Delprado, W., Henshall, S., Sutherland, R., Kench, J. (2012), High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy. BJU International. 109(12), 1794-1800. [Abstract]
• Chua, W., Horvath, L., Beale, P., Clarke, S. (2012), Reporting clinical trial information: colorectal cancer trials at Sydney Cancer Centre. Internal Medicine Journal. 42(4), 416-421. [Abstract]
• Venkateswaran, L., Butow, P., Jansen, J., Wilcken, N., Wong, M., Hui, R., Szonyi, G., Gebski, V., Naganathan, V., Horvath, L., Tattersall, M. (2012), Decision making in older patients with advanced cancer: does doctor know best?. Medical Journal of Australia. 196(1), 35-36. [Abstract]

2011

• Yip, P., Kench, J., Rasiah, K., Benito, R., Lee, C., Stricker, P., Henshall, S., Sutherland, R., Horvath, L. (2011), Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer. The Prostate. 71(15), 1638-45. [Abstract]
• Mahon, K., Henshall, S., Sutherland, R., Horvath, L. (2011), Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocrine-Related Cancer. 18(4), R103-123. [Abstract]
• Kench, J., Clouston, D., Delprado, W., Eade, T., Ellis, D., Horvath, L., Samaratunga, H., Stahl, J., Stapleton, A., Egevad, L., Srigley, J., Delahunt, B. (2011), Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens. Pathology. 43(5), 410-9. [Abstract]
• Leighl, N., Shepherd, H., Butow, P., Clarke, S., McJannett, M., Beale, P., Wilcken, N., Moore, M., Chen, E., Goldstein, D., Horvath, L., Knox, J., Krzyzanowska, M., Oza, A., Feld, R., Hedley, D., Xu, W., Tattersall, M. (2011), Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(15), 2077-84. [Abstract]
• Cooper, W., O'toole, S., Boyer, M., Horvath, L., Mahar, A. (2011), What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology. 43(2), 103-115. [Abstract]
• Devaney, J., Stirzaker, C., Qu, W., Song, J., Statham, A., Patterson, K., Horvath, L., Tabor, B., Coolen, M., Hulf, T., Kench, J., Henshall, S., Pe Benito, R., Haynes, A., Mayor, R., Peinado, M., Sutherland, R., Clark, S. (2011), Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkers. Cancer Epidemiology, Biomarkers & Prevention. 20(1), 148-159. [Abstract]

2010

• Ocean, A., Polite, B., Christos, P., Horvath, L., Hamilton, A., Matulich, D., Chen, H., Sparano, J., Kindler, H. (2010), Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. Clinical Colorectal Cancer. 9(5), 290-296. [Abstract]
• Bianco-Miotto, T., Chiam, K., Buchanan, G., Jindal, S., Day, T., Thomas, M., Pickering, M., O'Loughlin, M., Ryan, N., Raymond, W., Horvath, L., Kench, J., Stricker, P., Marshall, V., Sutherland, R., Henshall, S., Gerald, W., Scher, H., Risbridger, G., Clements, J., Butler, L., Tilley, W., Horsfall, D., Ricciardelli, C. (2010), Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 19(10), 2611-22. [Abstract]
• Thanigasalam, R., Rasiah, K., Stricker, P., Haynes, A., Sutherland, S., Sutherland, R., Henshall, S., Horvath, L. (2010), Stage migration in localized prostate cancer has no effect on the post-radical prostatectomy Kattan nomogram. BJU international. 105(5), 642-7. [Abstract]

2009

• Karim, R., Gerega, S., Yang, Y., Horvath, L., Spillane, A., Carmalt, H., Scolyer, R., Lee, C. (2009), Proteins from the Wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours. Journal of Clinical Pathology. 62(11), 1016-1020. [Abstract]
• Zhao, L., Lee, B., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Kaplan, W., Breit, S., Sutherland, R., Henshall, S., Horvath, L. (2009), Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Research. 69(19), 7696-7703. [Abstract]
• Tattersall, M., Dear, R., Jansen, J., Shepherd, H., J Devine, R., G Horvath, L., Boyer, M. (2009), Second opinions in oncology: the experiences of patients attending the Sydney Cancer Centre. Medical Journal of Australia. 191(4), 209-212. [Abstract]
• Balanathan, P., Williams, E., Wang, H., Pedersen, J., Horvath, L., Achen, M., Stacker, S., Risbridger, G. (2009), Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer. British Journal of Cancer. 100(11), 1784-1793. [Abstract]

2008

• Ho, L., Kench, J., Handelsman, D., Scheffer, G., Stricker, P., Grygiel, J., Sutherland, R., Henshall, S., Allen, J., Horvath, L. (2008), Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer. The Prostate. 68(13), 1421-9. [Abstract]
• Sakko, A., Butler, M., Byers, S., Reinboth, B., Stahl, J., Kench, J., Horvath, L., Sutherland, R., Stricker, P., Henshall, S., Marshall, V., Tilley, W., Horsfall, D., Ricciardelli, C. (2008), Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 17(9), 2488-2497. [Abstract]
• Seng, T., Currey, N., Cooper, W., Lee, C., Chan, C., Horvath, L., Sutherland, R., Kennedy, C., McCaughan, B., Kohonen-Corish, M. (2008), DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. British journal of cancer. 99(2), 375-82. [Abstract]

2007

• Horvath, L., Lelliott, J., Kench, J., Lee, C., Williams, E., Saunders, D., Grygiel, J., Sutherland, R., Henshall, S. (2007), Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer. The Prostate. 67(10), 1081-1090. [Abstract]